Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma

Next Previous
X
Search
Trial Profile

A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary) ; Epinephrine; Loratadine; Mometasone; Olopatadine
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors ALK-Abello; Merck Sharp & Dohme

    • Most Recent Events

    • 08 Nov 2021 Results of pooled post hoc analysis comparing efficacy and safety of the HDM SLIT-tablet between adults and adolescents by using data from two studies (NCT01700192 an JapicCTI21848) presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
    • 01 Mar 2021 Results assessing efficacy and safety data from 2 clinical trials (NCT01700192 and JapicCTI121848), presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top